AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24334945 — intervention group
Group type: COMPARATOR
Intervention: Larimal (artesunate plus amodiaquine)
Number of subjects: 182
Study 21092353 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted CBT combined with antidepressants
Number of subjects: 34
Study 21092353 — intervention group
Group type: COMPARATOR
Intervention: Antidepressants alone (treatment as usual)
Number of subjects: 34
Study 19329835 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-calcium containing phosphate binder
Number of subjects: 0
Study 19329835 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcimimetics
Number of subjects: 0
Study 19329835 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 17667736 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS)
Number of subjects: 11
Study 17667736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 15359542 — intervention group
Group type: EXPERIMENTAL
Intervention: Test Dentifrice (1.0% hydrogen peroxide, 0.243% sodium fluoride, sodium tripolyphosphate)
Number of subjects: 44
Study 15359542 — intervention group
Group type: COMPARATOR
Intervention: Control Dentifrice (0.243% sodium fluoride in a silica base)
Number of subjects: 44
Study 15359542 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Test Dentifrice to Control Dentifrice
Number of subjects: 44
Study 11444081 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular aerobic exercise training
Number of subjects: 140
Study 11444081 — intervention group
Group type: COMPARATOR
Intervention: Reference group (control)
Number of subjects: 140
Study 11444081 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall group
Number of subjects: 140
Study 11444081 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with low energy-adjusted calcium intake
Number of subjects: 140
Study 11444081 — intervention group
Group type: EXPERIMENTAL
Intervention: Men who increased alcohol intake during the intervention
Number of subjects: 140
Study 11444081 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term regular aerobic physical activity
Number of subjects: 140
Study 11444081 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar BMD
Number of subjects: 140
Study 9745397 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (100 or 250 micrograms, sc, every 8 h for 6 months)
Number of subjects: 107
Study 7988854 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (3.6 mg goserelin depot injection on cycle day 22 followed by individualized HMG stimulation 14 days later)
Number of subjects: 62
Study 7988854 — intervention group
Group type: COMPARATOR
Intervention: HMG stimulation starting on cycle day 3
Number of subjects: 62
Study 2659475 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with slow-release theophylline (2 x 350 mg) and salbutamol aerosol
Number of subjects: 40
Study 2659475 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol monotherapy (placebo capsules)
Number of subjects: 40
Study 2659475 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with slow-release theophylline and salbutamol aerosol
Number of subjects: 40
Study 1148964 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephaloridine (prophylactic antibacterial therapy)
Number of subjects: 266
Study 1148964 — intervention group
Group type: COMPARATOR
Intervention: No cephaloridine (control group)
Number of subjects: 266
Study 28524025 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (0.05 mg×kg‐1×h‐1, titrated to decrease heart rate by 20% or below 95 bpm)
Number of subjects: 60
Study 28524025 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 60
Study 28524025 — intervention group
Group type: COMPARATOR
Intervention: Control (isotonic saline at 3 mL/h for 24 hours)
Number of subjects: 60
Study 25733127 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet suction technique (WEST)
Number of subjects: 0
Study 25733127 — intervention group
Group type: COMPARATOR
Intervention: Conventional FNA technique (CFNAT)
Number of subjects: 0
Study 23937598 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental condition (impaired control paradigm)
Number of subjects: 39
Study 23937598 — intervention group
Group type: COMPARATOR
Intervention: Free-drinking condition
Number of subjects: 39
Study 21948965 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 400 mg three times daily for 20 days
Number of subjects: 68
Study 21948965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 19838080 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap and TIV co-administered
Number of subjects: 1497
Study 19838080 — intervention group
Group type: COMPARATOR
Intervention: Tdap and TIV sequential administration (TIV followed by Tdap)
Number of subjects: 1497
Study 16759390 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein supplementation (10 mg/d for 12 weeks followed by 30 mg/d for 12 weeks)
Number of subjects: 34
Study 16759390 — intervention group
Group type: COMPARATOR
Intervention: Placebo (24 weeks)
Number of subjects: 34
Study 16759390 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein supplementation
Number of subjects: 34
Study 16759390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 15568661 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose morning omeprazole
Number of subjects: 53
Study 15568661 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose morning rabeprazole
Number of subjects: 53
Study 15568661 — intervention group
Group type: COMPARATOR
Intervention: Single-dose morning famotidine
Number of subjects: 53
Study 15568661 — intervention group
Group type: COMPARATOR
Intervention: Single-dose evening omeprazole
Number of subjects: 53
Study 15568661 — intervention group
Group type: COMPARATOR
Intervention: Single-dose evening rabeprazole
Number of subjects: 53
Study 10998014 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitization to indoor allergens with bronchial hyperresponsiveness (BHR)
Number of subjects: 1904
Study 10998014 — intervention group
Group type: EXPERIMENTAL
Intervention: Low levels of specific IgE to indoor allergens with BHR
Number of subjects: 1904
Study 10998014 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitization to outdoor allergens
Number of subjects: 1904
Study 10998014 — intervention group
Group type: COMPARATOR
Intervention: Subjects with specific IgE to inhalant allergens (asymptomatic)
Number of subjects: 1904
Study 9489411 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of chronic pulmonary tuberculosis with 4-6 antituberculous drugs for not less than one year after sputum culture conversion.
Number of subjects: 48
Study 9489411 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy with 3 or 4 drugs for recently diagnosed pulmonary tuberculosis.
Number of subjects: 48
Study 8454118 — intervention group
Group type: EXPERIMENTAL
Intervention: Time spent on health education
Number of subjects: 100
Study 8454118 — intervention group
Group type: EXPERIMENTAL
Intervention: Time spent on physical examination
Number of subjects: 100
Study 8454118 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of treatment effects
Number of subjects: 100
Study 8454118 — intervention group
Group type: EXPERIMENTAL
Intervention: Time spent on history taking
Number of subjects: 100
Study 3530303 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine
Number of subjects: 10
Study 3530303 — intervention group
Group type: COMPARATOR
Intervention: Digoxin + Placebo
Number of subjects: 10
Study 31901231 — intervention group
Group type: EXPERIMENTAL
Intervention: SOFT block with bupivacaine 0.25%
Number of subjects: 107
Study 31901231 — intervention group
Group type: COMPARATOR
Intervention: Spinal anaesthesia with hyperbaric bupivacaine 0.5% (7.5-10mg)
Number of subjects: 107
Study 30395878 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐Sil dressings
Number of subjects: 120
Study 30395878 — intervention group
Group type: COMPARATOR
Intervention: Conventional dressings (CD)
Number of subjects: 120
Study 29183926 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced management with 3 monthly follow-up
Number of subjects: 100
Study 29183926 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual by the general practitioner
Number of subjects: 100
Study 29183926 — intervention group
Group type: COMPARATOR
Intervention: Parallel observational group (no cognitive decline)
Number of subjects: 100
Study 25752882 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg DEX
Number of subjects: 47
Study 25752882 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg DEX
Number of subjects: 47
Study 25752882 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic DEX (4 mg) vs. steroid naïve cohort
Number of subjects: 47
Study 24460303 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - Perioperative comprehensive supportive care interventions including health education, psychological support, stress management, coping strategies, and behavior training.
Number of subjects: 60
Study 24460303 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG)
Number of subjects: 60
Study 24460303 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 60
Study 21775756 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 14
Study 19197729 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine and cyclophosphamide with rituximab (FCR)
Number of subjects: 139
Study 19197729 — intervention group
Group type: COMPARATOR
Intervention: Fludarabine and cyclophosphamide (FC)
Number of subjects: 139
Study 17004982 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferrous sucrose 200 mg (two doses on days 2 and 4)
Number of subjects: 44
Study 17004982 — intervention group
Group type: COMPARATOR
Intervention: Oral ferrous sulphate 200 mg twice daily for 6 weeks
Number of subjects: 44
Study 17004982 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferrous sucrose
Number of subjects: 44
Study 17004982 — intervention group
Group type: COMPARATOR
Intervention: Oral ferrous sulphate
Number of subjects: 44
Study 14762881 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation (60-66 Gy over 30-33 daily fractions)
Number of subjects: 488
Study 14762881 — intervention group
Group type: COMPARATOR
Intervention: Surgery (horizontal or vertical partial laryngectomy, various minor procedures)
Number of subjects: 488
Study 14762881 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation
Number of subjects: 488
Study 14762881 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 488
Study 15635849 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (3 times per week for 2 months on a bicycle ergometer)
Number of subjects: 38
Study 15635849 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 38
Study 9205634 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1000 mg effervescent calcium tablet, Sandocal 1000)
Number of subjects: 42
Study 9205634 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 42
Study 9205634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 7960357 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% 8-MOP bathing suit treatment
Number of subjects: 24
Study 7960357 — intervention group
Group type: COMPARATOR
Intervention: Placebo bathing suit treatment
Number of subjects: 24
Study 3446438 — intervention group
Group type: EXPERIMENTAL
Intervention: Norinyl 1/35
Number of subjects: 300
Study 3446438 — intervention group
Group type: COMPARATOR
Intervention: Brevicon
Number of subjects: 300
Study 31634752 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (3 sessions of 50 minutes per week for 12 weeks)
Number of subjects: 0
Study 31634752 — intervention group
Group type: COMPARATOR
Intervention: Balance and tone program (control condition)
Number of subjects: 0
Study 29437941 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (40 mg.kg(‐1))
Number of subjects: 61
Study 29437941 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride (placebo)
Number of subjects: 61
Study 29437941 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate
Number of subjects: 61
Study 27686002 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose azathioprine in combination with allopurinol
Number of subjects: 46
Study 27686002 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine monotherapy
Number of subjects: 46
Study 25070123 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal therapy using an infrared thermal blanket at 50°C for 40 minutes in addition to drug treatment
Number of subjects: 38
Study 25070123 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 38
Study 22768642 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate
Number of subjects: 108
Study 22768642 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin conductance level (SCL)
Number of subjects: 108
Study 22768642 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate and SCL combined
Number of subjects: 108
Study 20558906 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute normobaric hypoxia (O2: 14.4%)
Number of subjects: 9
Study 20558906 — intervention group
Group type: COMPARATOR
Intervention: Normobaric normoxia
Number of subjects: 9
Study 18485668 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape antioxidant dietary fiber (7.5 g/d)
Number of subjects: 34
Study 18485668 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape antioxidant dietary fiber (7.5 g/d) in hypercholesterolemic subjects
Number of subjects: 34
Study 18485668 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-supplemented non-smokers)
Number of subjects: 34
Study 16164654 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-phase patient-centered educational intervention (educational booklets, 15-minute video, 90-minute small group session) in addition to regular multidisciplinary care
Number of subjects: 70
Study 16164654 — intervention group
Group type: COMPARATOR
Intervention: Ongoing standard care and education in the multidisciplinary predialysis clinic
Number of subjects: 70
Study 11476456 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 15 mg twice daily
Number of subjects: 875
Study 11476456 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 30 mg twice daily
Number of subjects: 875
Study 11476456 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 60 mg twice daily
Number of subjects: 875
Study 11476456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 875
Study 9595871 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg taken 5 hours before the endogenous nocturnal plasma melatonin concentration reached 10 pg/mL
Number of subjects: 30
Study 7802194 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase 50 u.ml‐1 added to local anaesthetic mixture
Number of subjects: 60
Study 7802194 — intervention group
Group type: COMPARATOR
Intervention: Standardised local anaesthetic mixture without hyaluronidase (Control)
Number of subjects: 60
Study 15235828 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous famotidine (20 mg administered one hour before surgery)
Number of subjects: 128
Study 15235828 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular famotidine (20 mg administered one hour before surgery)
Number of subjects: 128
Study 15235828 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral famotidine (20 mg administered the night before and on the morning of surgery)
Number of subjects: 128
Study 15235828 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo, no famotidine)
Number of subjects: 128
Study 31550073 — intervention group
Group type: EXPERIMENTAL
Intervention: MM-BK model
Number of subjects: 0
Study 31550073 — intervention group
Group type: EXPERIMENTAL
Intervention: QSS model
Number of subjects: 0
Study 31550073 — intervention group
Group type: EXPERIMENTAL
Intervention: MM-IDR model
Number of subjects: 0
Study 30452208 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention (mailed materials and telephone support)
Number of subjects: 561
Study 30452208 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 561
Study 29122253 — intervention group
Group type: EXPERIMENTAL
Intervention: Nature sounds
Number of subjects: 93
Study 29122253 — intervention group
Group type: EXPERIMENTAL
Intervention: Silence (headphones without sound)
Number of subjects: 93
Study 29122253 — intervention group
Group type: COMPARATOR
Intervention: Control (routine care only)
Number of subjects: 93
Study 23244443 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based strategies for recruitment (changing inclusion criteria, increasing study staff, branding the study, respectful engagement, pacing the process)
Number of subjects: 0
Study 23244443 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivators for participation
Number of subjects: 0
Study 23244443 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment expenditures
Number of subjects: 0
Study 21332976 — intervention group
Group type: EXPERIMENTAL
Intervention: AMC/DCBA Warm lozenge
Number of subjects: 225
Study 21332976 — intervention group
Group type: EXPERIMENTAL
Intervention: AMC/DCBA Cool lozenge
Number of subjects: 225
Study 21332976 — intervention group
Group type: COMPARATOR
Intervention: Unflavoured, non‐medicated lozenge
Number of subjects: 225
Study 19820024 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/d)
Number of subjects: 12
Study 19820024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16731209 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based speed-of-processing training (8 to 10 sessions of 1 hour each)
Number of subjects: 181
Study 16731209 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 181
Study 15599677 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-CRP levels measured at baseline and follow-up after 6 months
Number of subjects: 133
Study 15599677 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-CRP levels in patients without cardiac events
Number of subjects: 133
Study 15599677 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-CRP levels in patients with cardiac events
Number of subjects: 133
Study 15599677 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-CRP levels above 60% of initial level
Number of subjects: 133
Study 11310517 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 400 mg
Number of subjects: 10
Study 11310517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9636952 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean tissue mass
Number of subjects: 41
Study 9636952 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight
Number of subjects: 41
Study 9636952 — intervention group
Group type: COMPARATOR
Intervention: Gymnasts (subgroup)
Number of subjects: 41
Study 9636952 — intervention group
Group type: COMPARATOR
Intervention: Swimmers (subgroup)
Number of subjects: 41
Study 7930249 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography (Group I)
Number of subjects: 61
Study 7930249 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography (Group II)
Number of subjects: 61
Study 7930249 — intervention group
Group type: COMPARATOR
Intervention: No significant coronary artery disease
Number of subjects: 61
Study 2765272 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat high polyunsaturated fatty acids/saturated fatty acid ratio diet
Number of subjects: 0
Study 2765272 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased intake of saturated fats
Number of subjects: 0
Study 30802929 — intervention group
Group type: EXPERIMENTAL
Intervention: Homotopic heat stimuli at 45 °C
Number of subjects: 18
Study 30802929 — intervention group
Group type: EXPERIMENTAL
Intervention: Homotopic heat stimuli at 50 °C
Number of subjects: 18
Study 30802929 — intervention group
Group type: COMPARATOR
Intervention: Heterotopic counterstimuli
Number of subjects: 18
Study 27888416 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK239512
Number of subjects: 131
Study 27888416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 25384069 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Number of subjects: 1175
Study 25384069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1175
Study 23759474 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping Screen (4-item tool)
Number of subjects: 6210
Study 23759474 — intervention group
Group type: EXPERIMENTAL
Intervention: PHQ-2 and GAD-2
Number of subjects: 6210
Study 23759474 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic item
Number of subjects: 6210
Study 21683485 — intervention group
Group type: EXPERIMENTAL
Intervention: Specially formulated medical food (40 g protein, enriched with 10% free leucine)
Number of subjects: 25
Study 21683485 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical food (24 g casein protein)
Number of subjects: 25
Study 19921981 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice 50 ml daily (n=28)
Number of subjects: 84
Study 19921981 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG drink 100 ml on 5 days a month (n=27)
Number of subjects: 84
Study 19921981 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=29)
Number of subjects: 84
Study 23850844 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic postconditioning (RIP)
Number of subjects: 232
Study 23850844 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic postconditioning (RIP) in diabetic patients
Number of subjects: 232
Study 23850844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study 15855510 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg intravenous infusion over 30 min t.i.d.
Number of subjects: 16
Study 15855510 — intervention group
Group type: COMPARATOR
Intervention: 250 mg loading dose followed by 1,500 mg continuous infusion over 24 h
Number of subjects: 16
Study 15855510 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg intravenous infusion over 30 min t.i.d.
Number of subjects: 16